ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DERM vs MENS // FREE CASH FLOW YIELD

Journey Medical Corporation (NASDAQ) VS. Jyong Biotech Ltd. (NASDAQ) • 15-METRIC TALLY: DERM 3 — MENS 2
▲ FREE CASH FLOW YIELD LEADER: MENS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. MENS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DERM MENS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 65.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -19.50% -28.80% +9.30 DERM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -8.15% -2.13% -6.02 MENS /fcf-yield <GO>
Operating Margin -13.30% — — TIE /operating-margins <GO>
Net Profit Margin -18.70% — — TIE /net-margins <GO>
Revenue Growth (YoY) 11.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.74 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 DERM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 45.7 -5.20 MENS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $145.9M $142.9M $3.0M DERM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DERM REV MENS REV DERM GROSS % MENS GROSS % DERM FCF MENS FCF
FY 2025 $61.2M $7.3M 65.8% — -$12.4M -$3.0M
FY 2024 $55.1M $5.8M 62.1% — -$9.1M -$3.6M
FY 2023 $59.7M $7.8M — — $5.2M -$2.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
MENS // BETA —